An interventional study of Acupuncture and myofascial therapy in Chronic Pain, sponsored by David Moss. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by David Moss · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.
Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 312th largest by planned enrollment of the 1,092 interventional ones that give a count, is one of 92 that started in 2025, is one of 803 with no phase, reaches primary completion later than 281 of the 347 other live ones, and was the 1,181st registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:
University of Oklahoma · Sites in United States
Ages 18–120
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18+ · Women only
University of Massachusetts, Boston · Sites in United States
Ages 65+
Stanford University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 112 · Phase 3 72 · Phase 4 50
First in 1992; this study’s year is marked. 92 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 60 across the 1,092 interventional studies, 100 across the 189 observational. Of the 848 that completed or were terminated, 386 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
209 of 1,283 have an industry lead sponsor. The 10 most frequent:
David Moss is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
David Moss has 1 study filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
139 of the studies in Chronic Pain with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT06091202Phase 3Oregon Health and Science UniversityTele-Collaborative Outreach to Rural Patients With Chronic Pain | 2027-05-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT03984565Staci Gruber, Ph.D.PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 1,283 studies in Chronic Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
With vast numbers of active-duty members restricted from their specific duties or deemed unfit for deployment because of low back pain, both the mission of the Department of Defense and overall military workflow can be significantly impacted. More than restriction from duty or being barred from deployment, studies have shown musculoskeletal conditions were among the top reasons for medical disability retirement in the Army and Marine Corps (Niebuhr; Sikorski). Given the significant time, money, and resources invested in training these members, each day of inactivity or disability detrimentally affects the execution of the military's mission. Therefore, precise diagnosis and effective treatment modalities are paramount to foster healing and reduce recovery time.
From an operational standpoint, the United States Department of Defense (DoD) is specifically interested in using tailored integrative medicine modalities to manage chronic conditions encountered in the military health system. Not just chronic pain, but polytrauma and the triad of conditions it encompasses; traumatic brain injury and post-traumatic stress disorder combined with chronic pain (Madsen, Kim, Bedard). The DoD's goal is also to decrease opioid prescribing and the addiction and altered state associated with opioids.
AT the Nellis Integrative Medicine Clinic, physicians, a chiropractor, and nurses are engaged in the treatment of patients. All personnel are trained in the various modalities available in the clinics.
A variety of modalities are utilized in the clinic. This prospective study will evaluate the effectiveness of the many modalities used in the Integrative Medicine Clinic (such as acupuncture, myofascial therapies, microcurrent therapies, LASER therapy, extracorporeal shockwave therapy, and pulsed electromagnetic therapies).
Most patients receive treatments using multiple modalities. DoD goals align with our experiences in the Integrative Medicine Clinic at Mike O'Callaghan Military Medical Center. Many servicemembers and dependents in our clinic are trying to avoid surgery, or their pain medications - opioid or not - are no longer working. Additionally, many patients are trying to avoid Do Not Fly status caused by pharmacologic approaches. Patient experiences at our IMC also correlate with a study where 80% of people surveyed felt integrative medicine should be routinely offered at all MTFs (Ross). While our patients generally are not on opioids, we have anecdotally noted a reduction or cessation of opioids in several patients. The impacts of such a reduction in opioid usage for military readiness is clear (Madsen).
All of the below items are research-related unless marked as 'standard of care'. Visits will vary depending on provider-decided treatments and will generally range from 30 minutes to 2 hours in length.
Self-reported pain intensity assessment.
Screening visit (1 hour):
Collect additional information to include:
SURVEY RELATED VISITS
Visit 1 (week 0 can be the same day as screening visit) (30 minutes) (In-person or Virtual):
BASELINE
Visit 2 (Week 4) (60 minutes) (In-person or Virtual) Research coordinator with record morphine milligram equivalents (MME) for patients taking opioid medications.
Visit 3 (Week 8) (60 Minutes) (In-person or Virtual) Research coordinator with record morphine milligram equivalents (MME) for patients taking opioid medications.
Visit 4 (Week 12) (60 Minutes) (In-person or Virtual) Research coordinator with record morphine milligram equivalents (MME) for patients taking opioid medications.
Visit 5 (Week 16) (60 minutes) (In-person or Virtual) Research coordinator with record morphine milligram equivalents (MME) for patients taking opioid medications.
Visit 6 (Week 20) (60 minutes) (In-person or Virtual) Research coordinator with record morphine milligram equivalents (MME) for patients taking opioid medications.
Visit 7 (Week 24) (60 minutes) (In-person or Virtual) Research coordinator with record morphine milligram equivalents (MME) for patients taking opioid medications.
Visit 8 (Week 28) (60 minutes) (In-person or Virtual) Research coordinator with record morphine milligram equivalents (MME) for patients taking opioid medications.
TREATMENT VISITS Treatments given in Integrative Medicine Clinic will be at provider discretion. Subjects will attend a minimum of 3 visits then additional treatment sessions will be at provider discretion as well.
The following semi structured clinical algorithm will be used by providers in the clinic.
Visit 1:
Home Exercise Program handout (Rx3)
Visit 2:
Re-education of TA activation, additional myofascial work as needed (including lower trap and
/or glut med activation)
create plan for visit 3 (this could include additional myofascial work, shock wave therapy, acupuncture/dry needling, avazzia or alpha stim)
Visits 3 through final:
a. Myofascial treatments (functional neuromyofascial techniques [FNT], cupping, gua sha, active needling) b. Frequency Specific Microcurrent (FSM) c. Avazzia d. Extracorporeal shock wave therapy (ESWT) e. Acupuncture/dry needling f. Alpha stim (cranio-electric stimulation) Coordinators will monitor subject visits either in-person post each visit or by accessing the EMR post each visit to record visit details. Visit Details to Record
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
**Patients must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study**
Inclusion Criteria:
Exclusion Criteria:
Enrolled in other pain management program (e.g. pain management, PT
/OT)
Patients will act as their own control with preintervention scores. The main integrative medicine intervention therapies include but may not be limited to acupuncture, myofascial therapies, microcurrent therapies, LASER therapy, extracorporeal shockwave therapy, and pulsed electromagnetic therapies.
Other: Acupuncture · Other: myofascial therapy · Other: microcurrent therapy · Other: LASER · Other: extracorporeal shockwave therapy · Other: Pulsed electromagnetic therapies · Other: Miscellaneous integrative medicine
Integrative Medicine: Acupuncture treatment
Integrative Medicine: myofascial therapy to include transverse abdominus teaching, rectus abdominus release, functional neuromyofascial techniques, cupping, gua sha, active needling.
Integrative Medicine: Microcurrent
Integrative Medicine: LASER
Integrative Medicine: Extracorporeal shockwave therapy
Integrative Medicine: Pulsed electromagnetic therapies
other integrative medicine modalities
Dallas Pain Questionnaire
16 item quality of life questionnaire assessing multiple domains
Time frame: baseline (pre-treatment) through study period (visit 1, week 0) (visit 2, week 4) (visit 3, week 8) (visit 4, week 12) (visit 5, week 16) (visit 6, week 20) (visit 4, week 24) (visit 8, week 28)
PROMIS physical function form 6b
6 questions evaluating physical function
Time frame: baseline (pre-treatment) through study period (visit 1, week 0) (visit 2, week 4) (visit 3, week 8) (visit 4, week 12) (visit 5, week 16) (visit 6, week 20) (visit 4, week 24) (visit 8, week 28)
Defense and Veterans Pain Rating Scale
pain assessment tool using numerical rating scale enhanced by functional word descriptors, color coding, and pictorial facial expressions
Time frame: baseline (pre-treatment) through study period (visit 1, week 0) (visit 2, week 4) (visit 3, week 8) (visit 4, week 12) (visit 5, week 16) (visit 6, week 20) (visit 4, week 24) (visit 8, week 28)
PEG (pain average, enjoyment of life, and general activity)
assesses pain intensity and interference
Time frame: baseline (pre-treatment) through study period (visit 1, week 0) (visit 2, week 4) (visit 3, week 8) (visit 4, week 12) (visit 5, week 16) (visit 6, week 20) (visit 4, week 24) (visit 8, week 28)
Patient Health Questionnaire 2-item (PHQ-2)
measures depressed mood and anhedonia over past 2 weeks
Time frame: baseline (pre-treatment) through study period (visit 1, week 0) (visit 2, week 4) (visit 3, week 8) (visit 4, week 12) (visit 5, week 16) (visit 6, week 20) (visit 4, week 24) (visit 8, week 28)
Patient health questionnaire 9-item
measures more detailed depressed mood and anhedonia if patient scores 3 or higher on phq-2
Time frame: baseline (pre-treatment) through study period (visit 1, week 0) (visit 2, week 4) (visit 3, week 8) (visit 4, week 12) (visit 5, week 16) (visit 6, week 20) (visit 4, week 24) (visit 8, week 28)
Generalized Anxiety Disorder 2-item
screening tool for generalized anxiety disorder
Time frame: baseline (pre-treatment) through study period (visit 1, week 0) (visit 2, week 4) (visit 3, week 8) (visit 4, week 12) (visit 5, week 16) (visit 6, week 20) (visit 4, week 24) (visit 8, week 28)
Generalized Anxiety Disorder 7-item
extended screening tool for generalized anxiety disorder to use if subjects score 3 or higher on GAD-2
Time frame: baseline (pre-treatment) through study period (visit 1, week 0) (visit 2, week 4) (visit 3, week 8) (visit 4, week 12) (visit 5, week 16) (visit 6, week 20) (visit 4, week 24) (visit 8, week 28)
Pain Catastrophizing Scale
quantifies pain experience (rumination, magnification, and helplessness)
Time frame: baseline (pre-treatment) through study period (visit 1, week 0) (visit 2, week 4) (visit 3, week 8) (visit 4, week 12) (visit 5, week 16) (visit 6, week 20) (visit 4, week 24) (visit 8, week 28)
Pittsburgh Sleep Quality Index
Self-report questionnaire that assesses sleep quality over a one-month time interval. The global score ranges from 0 to 21. Higher scores indicate poorer sleep quality.
Time frame: baseline (pre-treatment) through study period (visit 1, week 0) (visit 2, week 4) (visit 3, week 8) (visit 4, week 12) (visit 5, week 16) (visit 6, week 20) (visit 4, week 24) (visit 8, week 28)
Plan to share: Yes — Demographic and clinical data will be acquired from 125 participants. All data will be de-identified prior to receipt by the repository, but the information needed to generate a global unique identifier for the NLM Data Archive (NDA) (clinicaltrials.gov) will be collected for each subject. Sufficient data from this project will be preserved to enable sharing via NDA data of sufficient quality to validate and replicate research findings described in the Aims. NLM requires data measured from human subjects to be shared using the NDA. Demographic data, clinical data, data collection tools and study protocols will be made available in the NDA.
Supporting information: Study protocol, Informed consent form
Time frame: All data will be deposited to clinicaltrials.gov starting 12 months after the award begins and will be deposited every six months thereafter following the usual NDA data submission dates.
Access criteria: Data will be findable for the research community through the NDA Collection that will be established when this application is funded. For all publications, an NDA study will be created. Each of those studies is assigned a digital object identifier (DOI). This data DOI will be referenced in the publication to allow the research community easy access to the exact data used in the publication. The research community will have access to data when the award ends. As required by NDA, studies will also be created that contain the data used for every publication. Those studies will be shared when the pre-print is available. NDA studies have digital object identifiers (DOI) to aid in findability. We will include that DOI in relevant publications. NDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jul 2028, 35 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 35 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
David Moss